CAAS vFFR is an angiographic method used to assess coronary physiology and calculate fractional flow reserve (FFR) values. The vFFR value indicates the significance of specific coronary lesions and shows where blood flow is limited. Furthermore, the 3D reconstruction enables the severity and percentage of stenosis to be assessed. Use of this novel method is supported by several clinical studies (e.g., FAST I; FAST Post) and shows promise as a replacement of the current gold standard, pressure wire invasive FFR measurement.1
Together with our partners European Cardiovascular Research Institute (ECRI), Pie Medical Imaging and under the leadership of Dr Joost Daemen the FAST III trial will investigate the outcome impact of vFFR-guided PCI in patients with stable coronary artery disease or non-ST elevation acute coronary syndrome with an indication for physiological assessment of intermediate coronary lesions compared to FFR-guided treatment in 2228 patients at 35 sites to further strengthen the body of evidence on the use of vFFR in the pursuit of a quicker and less stressful diagnosis, and lower cost of care.
